The Centers for Medicare and Medicaid Services will cover the high cost of Alzheimer’s drugs if the Food and Drug Administration grants traditional approval and when a physician and clinical team participates in the collection of evidence about how these drugs work in the real world, also known as a registry.
CMS announces plan to ensure availability of new Alzheimer’s drugs but stakeholders cry foul
